Five-year outcomes with nivolumab in patients with wild-type BRAF advanced melanoma
PURPOSEThe CheckMate 066 trial investigated nivolumab monotherapy as first-line treatment for patients with previously untreated BRAF wild-type advanced melanoma. Five-year results are presented herein.PATIENTS AND METHODSIn this multicenter, double-blind, phase III study, 418 patients with previous...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
September 30, 2020
|
| In: |
Journal of clinical oncology
Year: 2020, Jahrgang: 38, Heft: 33, Pages: 3937-3946 |
| ISSN: | 1527-7755 |
| DOI: | 10.1200/JCO.20.00995 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1200/JCO.20.00995 Verlag, lizenzpflichtig, Volltext: https://ascopubs.org/doi/10.1200/JCO.20.00995 
|
| Verfasserangaben: | Caroline Robert, MD, PhD; Georgina V. Long, PhD, MBBS; Benjamin Brady, MD; Caroline Dutriaux, MD, PhD; Anna Maria Di Giacomo, MD, PhD; Laurent Mortier, MD, PhD; Piotr Rutkowski, MD, PhD; Jessica C. Hassel, MD; Catriona M. McNeil, MD; Ewa Anna Kalinka, MD; Céleste Lebbé, MD; Julie Charles, MD, PhD; Micaela M. Hernberg, MD; Kerry J. Savage, MSc, MD; Vanna Chiarion-Sileni, MD; Catalin Mihalcioiu, MD; Cornelia Mauch, MD, PhD; Ana Arance, MD, PhD; Francesco Cognetti, MD; Lars Ny, MD; Henrik Schmidt, MD; Dirk Schadendorf, MD; Helen Gogas, MD, PhD; Jesús Zoco, MS; Sandra Re, MD,MB; Paolo A. Ascierto, MD; and Victoria Atkinson, MD |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1745984518 | ||
| 003 | DE-627 | ||
| 005 | 20220819091121.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 210129s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1200/JCO.20.00995 |2 doi | |
| 035 | |a (DE-627)1745984518 | ||
| 035 | |a (DE-599)KXP1745984518 | ||
| 035 | |a (OCoLC)1341389929 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Robert, Caroline |e VerfasserIn |0 (DE-588)1128449277 |0 (DE-627)882936972 |0 (DE-576)485924544 |4 aut | |
| 245 | 1 | 0 | |a Five-year outcomes with nivolumab in patients with wild-type BRAF advanced melanoma |c Caroline Robert, MD, PhD; Georgina V. Long, PhD, MBBS; Benjamin Brady, MD; Caroline Dutriaux, MD, PhD; Anna Maria Di Giacomo, MD, PhD; Laurent Mortier, MD, PhD; Piotr Rutkowski, MD, PhD; Jessica C. Hassel, MD; Catriona M. McNeil, MD; Ewa Anna Kalinka, MD; Céleste Lebbé, MD; Julie Charles, MD, PhD; Micaela M. Hernberg, MD; Kerry J. Savage, MSc, MD; Vanna Chiarion-Sileni, MD; Catalin Mihalcioiu, MD; Cornelia Mauch, MD, PhD; Ana Arance, MD, PhD; Francesco Cognetti, MD; Lars Ny, MD; Henrik Schmidt, MD; Dirk Schadendorf, MD; Helen Gogas, MD, PhD; Jesús Zoco, MS; Sandra Re, MD,MB; Paolo A. Ascierto, MD; and Victoria Atkinson, MD |
| 264 | 1 | |c September 30, 2020 | |
| 300 | |a 12 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 29.01.2021 | ||
| 520 | |a PURPOSEThe CheckMate 066 trial investigated nivolumab monotherapy as first-line treatment for patients with previously untreated BRAF wild-type advanced melanoma. Five-year results are presented herein.PATIENTS AND METHODSIn this multicenter, double-blind, phase III study, 418 patients with previously untreated, unresectable, stage III/IV, wild-type BRAF melanoma were randomly assigned 1:1 to receive nivolumab 3 mg/kg every 2 weeks or dacarbazine 1,000 mg/m2 every 3 weeks. The primary end point was overall survival (OS), and secondary end points included progression-free survival (PFS), objective response rate (ORR), and safety.RESULTSPatients were followed for a minimum of 60 months from the last patient randomly assigned (median follow-up, 32.0 months for nivolumab and 10.9 months for dacarbazine). Five-year OS rates were 39% with nivolumab and 17% with dacarbazine; PFS rates were 28% and 3%, respectively. Five-year OS was 38% in patients randomly assigned to dacarbazine who had subsequent therapy, including nivolumab (n = 37). ORR was 42% with nivolumab and 14% with dacarbazine; among patients alive at 5 years, ORR was 81% and 39%, respectively. Of 42 patients treated with nivolumab who had a complete response (20%), 88% (37 of 42) were alive as of the 5-year analysis. Among 75 nivolumab-treated patients alive and evaluable at the 5-year analysis, 83% had not received subsequent therapy; 23% were still on study treatment, and 60% were treatment free. Safety analyses were similar to the 3-year report.CONCLUSIONResults from this 5-year analysis confirm the significant benefit of nivolumab over dacarbazine for all end points and add to the growing body of evidence supporting long-term survival with nivolumab mono-therapy. Survival is strongly associated with achieving a durable response, which can be maintained after treatment discontinuation, even without subsequent systemic therapies. | ||
| 700 | 1 | |a Long, Georgina V. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Brady, Benjamin |e VerfasserIn |4 aut | |
| 700 | 1 | |a Dutriaux, Caroline |e VerfasserIn |4 aut | |
| 700 | 1 | |a Di Giacomo, Anna Maria |e VerfasserIn |4 aut | |
| 700 | 1 | |a Mortier, Laurent |e VerfasserIn |4 aut | |
| 700 | 1 | |a Rutkowski, Piotr |e VerfasserIn |4 aut | |
| 700 | 1 | |a Hassel, Jessica C. |d 1975- |e VerfasserIn |0 (DE-588)129790702 |0 (DE-627)480399069 |0 (DE-576)29783715X |4 aut | |
| 700 | 1 | |a McNeil, Catriona M. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Kalinka, Ewa Anna |e VerfasserIn |4 aut | |
| 700 | 1 | |a Lebbé, Céleste |e VerfasserIn |4 aut | |
| 700 | 1 | |a Charles, Julie |e VerfasserIn |4 aut | |
| 700 | 1 | |a Hernberg, Micaela M. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Savage, Kerry J. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Chiarion-Sileni, Vanna |e VerfasserIn |4 aut | |
| 700 | 1 | |a Mihalcioiu, Catalin |e VerfasserIn |4 aut | |
| 700 | 1 | |a Mauch, Cornelia |e VerfasserIn |4 aut | |
| 700 | 1 | |a Arance, Ana |e VerfasserIn |4 aut | |
| 700 | 1 | |a Cognetti, Francesco |e VerfasserIn |4 aut | |
| 700 | 1 | |a Ny, Lars |e VerfasserIn |4 aut | |
| 700 | 1 | |a Schmidt, Henrik |e VerfasserIn |4 aut | |
| 700 | 1 | |a Schadendorf, Dirk |d 1960- |e VerfasserIn |0 (DE-588)11142576X |0 (DE-627)499566076 |0 (DE-576)289702275 |4 aut | |
| 700 | 1 | |a Gogas, Helen |e VerfasserIn |4 aut | |
| 700 | 1 | |a Zoco, Jesús |e VerfasserIn |4 aut | |
| 700 | 1 | |a Re, Sandra |e VerfasserIn |4 aut | |
| 700 | 1 | |a Ascierto, Paolo A. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Atkinson, Victoria |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of clinical oncology |d Alexandria, Va. : American Society of Clinical Oncology, 1983 |g 38(2020), 33, Seite 3937-3946 |h Online-Ressource |w (DE-627)313116962 |w (DE-600)2005181-5 |w (DE-576)090887018 |x 1527-7755 |7 nnas |a Five-year outcomes with nivolumab in patients with wild-type BRAF advanced melanoma |
| 773 | 1 | 8 | |g volume:38 |g year:2020 |g number:33 |g pages:3937-3946 |g extent:12 |a Five-year outcomes with nivolumab in patients with wild-type BRAF advanced melanoma |
| 856 | 4 | 0 | |u https://doi.org/10.1200/JCO.20.00995 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://ascopubs.org/doi/10.1200/JCO.20.00995 |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20210129 | ||
| 993 | |a Article | ||
| 994 | |a 2020 | ||
| 998 | |g 11142576X |a Schadendorf, Dirk |m 11142576X:Schadendorf, Dirk |d 50000 |e 50000PS11142576X |k 0/50000/ |p 22 | ||
| 998 | |g 129790702 |a Hassel, Jessica C. |m 129790702:Hassel, Jessica C. |d 910000 |d 911300 |d 50000 |e 910000PH129790702 |e 911300PH129790702 |e 50000PH129790702 |k 0/910000/ |k 1/910000/911300/ |k 0/50000/ |p 8 | ||
| 999 | |a KXP-PPN1745984518 |e 3844413103 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"language":["eng"],"title":[{"title_sort":"Five-year outcomes with nivolumab in patients with wild-type BRAF advanced melanoma","title":"Five-year outcomes with nivolumab in patients with wild-type BRAF advanced melanoma"}],"origin":[{"dateIssuedDisp":"September 30, 2020","dateIssuedKey":"2020"}],"recId":"1745984518","type":{"bibl":"article-journal","media":"Online-Ressource"},"note":["Gesehen am 29.01.2021"],"relHost":[{"pubHistory":["1.1983 -"],"language":["eng"],"part":{"text":"38(2020), 33, Seite 3937-3946","year":"2020","volume":"38","issue":"33","pages":"3937-3946","extent":"12"},"title":[{"subtitle":"JCO : an American Society of Clinical Oncology journal","title":"Journal of clinical oncology","title_sort":"Journal of clinical oncology"}],"titleAlt":[{"title":"official journal of the American Society of Clinical Oncology"},{"title":"JCO"},{"title":"Journal of clinical oncology legacy archive (ASCO)"}],"type":{"bibl":"periodical","media":"Online-Ressource"},"origin":[{"publisherPlace":"Alexandria, Va. ; Baltimore, Md. [u.a.]","dateIssuedKey":"1983","publisher":"American Society of Clinical Oncology ; Lippincott Williams & Wilkins","dateIssuedDisp":"1983-"}],"recId":"313116962","corporate":[{"display":"American Society of Clinical Oncology","role":"isb"}],"note":["Fortsetzung der Druck-Ausgabe","Gesehen am 22.05.23"],"disp":"Five-year outcomes with nivolumab in patients with wild-type BRAF advanced melanomaJournal of clinical oncology","physDesc":[{"extent":"Online-Ressource"}],"id":{"eki":["313116962"],"issn":["1527-7755"],"zdb":["2005181-5"]}}],"id":{"eki":["1745984518"],"doi":["10.1200/JCO.20.00995"]},"physDesc":[{"extent":"12 S."}],"name":{"displayForm":["Caroline Robert, MD, PhD; Georgina V. Long, PhD, MBBS; Benjamin Brady, MD; Caroline Dutriaux, MD, PhD; Anna Maria Di Giacomo, MD, PhD; Laurent Mortier, MD, PhD; Piotr Rutkowski, MD, PhD; Jessica C. Hassel, MD; Catriona M. McNeil, MD; Ewa Anna Kalinka, MD; Céleste Lebbé, MD; Julie Charles, MD, PhD; Micaela M. Hernberg, MD; Kerry J. Savage, MSc, MD; Vanna Chiarion-Sileni, MD; Catalin Mihalcioiu, MD; Cornelia Mauch, MD, PhD; Ana Arance, MD, PhD; Francesco Cognetti, MD; Lars Ny, MD; Henrik Schmidt, MD; Dirk Schadendorf, MD; Helen Gogas, MD, PhD; Jesús Zoco, MS; Sandra Re, MD,MB; Paolo A. Ascierto, MD; and Victoria Atkinson, MD"]},"person":[{"display":"Robert, Caroline","role":"aut","given":"Caroline","family":"Robert"},{"family":"Long","display":"Long, Georgina V.","given":"Georgina V.","role":"aut"},{"display":"Brady, Benjamin","role":"aut","given":"Benjamin","family":"Brady"},{"display":"Dutriaux, Caroline","given":"Caroline","role":"aut","family":"Dutriaux"},{"family":"Di Giacomo","given":"Anna Maria","role":"aut","display":"Di Giacomo, Anna Maria"},{"family":"Mortier","role":"aut","given":"Laurent","display":"Mortier, Laurent"},{"display":"Rutkowski, Piotr","given":"Piotr","role":"aut","family":"Rutkowski"},{"display":"Hassel, Jessica C.","given":"Jessica C.","role":"aut","family":"Hassel"},{"family":"McNeil","given":"Catriona M.","role":"aut","display":"McNeil, Catriona M."},{"given":"Ewa Anna","role":"aut","display":"Kalinka, Ewa Anna","family":"Kalinka"},{"family":"Lebbé","role":"aut","given":"Céleste","display":"Lebbé, Céleste"},{"given":"Julie","role":"aut","display":"Charles, Julie","family":"Charles"},{"family":"Hernberg","role":"aut","given":"Micaela M.","display":"Hernberg, Micaela M."},{"family":"Savage","role":"aut","given":"Kerry J.","display":"Savage, Kerry J."},{"family":"Chiarion-Sileni","given":"Vanna","role":"aut","display":"Chiarion-Sileni, Vanna"},{"given":"Catalin","role":"aut","display":"Mihalcioiu, Catalin","family":"Mihalcioiu"},{"family":"Mauch","given":"Cornelia","role":"aut","display":"Mauch, Cornelia"},{"family":"Arance","given":"Ana","role":"aut","display":"Arance, Ana"},{"family":"Cognetti","role":"aut","given":"Francesco","display":"Cognetti, Francesco"},{"family":"Ny","role":"aut","given":"Lars","display":"Ny, Lars"},{"family":"Schmidt","display":"Schmidt, Henrik","role":"aut","given":"Henrik"},{"display":"Schadendorf, Dirk","role":"aut","given":"Dirk","family":"Schadendorf"},{"role":"aut","given":"Helen","display":"Gogas, Helen","family":"Gogas"},{"role":"aut","given":"Jesús","display":"Zoco, Jesús","family":"Zoco"},{"family":"Re","role":"aut","given":"Sandra","display":"Re, Sandra"},{"family":"Ascierto","display":"Ascierto, Paolo A.","role":"aut","given":"Paolo A."},{"given":"Victoria","role":"aut","display":"Atkinson, Victoria","family":"Atkinson"}]} | ||
| SRT | |a ROBERTCAROFIVEYEAROU3020 | ||